

# How the tumor is initiated ?

- 1. **Chemical** carcinogenesis
- 2. **Hormonal** carcinogenesis
- 3. **Viral** carcinogenesis
- 4. **Bacterial/parasitic** carcinogenesis
- 5. **Chronic inflammation** carcinogenesis
- 6. **Spontaneous** carcinogenesis  
as a sum of all things above

TEST

# 1. **Chemical** carcinogenesis

## **Carcinogen**

Any agent that produces cancer, e.g.  
tobacco smoke,  
certain industrial chemicals,  
ionizing radiation  
(such as X-rays and ultraviolet rays).

# Carcinogens

## 1. Genotoxic

(direct DNA damaging carcinogens)

produce DNA adducts;

one application is enough for tumor initiation

## 2. Non-Genotoxic

(damage DNA as result of secondary interactions,  
e.g. increase of oxidative stress, inflammation)

# Genotoxic Carcinogens – mutators

**Direct carcinogens**  
(no modification needed)

**Anti-tumoral  
chemotherapeutic drugs**  
(cyclophosphamide,  
busulfan, chlorambucil),

**beta-propiolactone**

**Acetylating and alkylating  
agents**

**Pro-carcinogens**  
that have to be modified  
by intracellular enzymes

**benzanthracene**  
(first pure carcinogen)


**3,4-benzpyrene**  
(isolated from coal tar)

**7,12-dimethylbenzanthracene**  
(most potent carcinogen)

**Aflatoxin B1**


**Aromatic Amines and Azo Dyes**

## Benzo[a]pyrene




cytochrome P-450  
Enzyme

arene oxide



DNA · NH<sub>2</sub>




## polycyclic aromatic hydrocarbons (PAHs)


### Benzo[a]pyrene

is initially oxidized, primarily by the microsomal NADPH- dependent cytochrome P-450, to several arene oxides.

**Benzo[a]pyrene derivatives can bind and damage DNA.**



**Benzo[a]pyrene itself can bind AR (Aryl hydrocarbon receptor) and activate gene expression: cytochromes, MAP kinases, IGF-1 (insulin-like growth factor)**



# Aflatoxin B<sub>1</sub>

certain strains of the fungi  
*Aspergillus flavus*  
and *A. parasiticus*

## Prevention trial in China

**oltipraz**, an inducer of aflatoxin metabolizing enzymes, significantly increased biomarkers of aflatoxin detoxification





Fig. 2. Aflatoxin B<sub>1</sub> metabolism in the liver.

# Non-Genotoxic Carcinogenes: Tumor Promoters




**DMBA**

**Olive oil - 6 months**




**NO tumors**

**DMBA Promotor = Croton oil - 6 months**



**Multiple tumors**

**Promotor = Croton oil - 6 months DMBA**



**NO tumors**

**Two-phase carcinogenesis of mouse skin**

# TUMOR PROMOTERS

1. Promoting agents are not carcinogenic per se
2. Can promote cancer after **very small doses** of initiating (true carcinogenic) agents
3. Promoting agents can wake tumors up **long time** after administration of initiating agent


Phorbol esters	Aplysiatoxin (algal toxin)	Teleocidin (fungal toxin)
<b>Hormones (estrogen)</b>		<b>Growth factors</b>

**Those substances promote growth of existing tumor clones evolved after mutation events**



# Phorbol ester (from croton oil)


12-O-tetradecanoylphorbol-13-acetate (TPA)



**TPA activates protein kinase C**

**TPA is cell-toxic, pro-inflammatory agent that increase vascular permeability**

**TPA induces INFLAMMATION, and pushes epithelial cells to propagate**



**Pre-existing Tumor cell got her chance to grow**

# Professions and industries associated with high risk of cancer

Aluminium industry	polycyclic aromatic hydrocarbons (PAHs)	Lung and bladder cancer
Coal industry	polycyclic aromatic hydrocarbons (PAHs)	Lung, bladder, skin, scrotum cancer
Shoemaking	Benzene	Lymphomas, leukemias
Furniture making	Wood dust	Nasopharyngeal cancer
Fuchsin dye production	Fuchsin, ortho-toluidine	Bladder cancer
Rubber industry	Aromatic amines, solvents	Lung, colon, stomach, bladder, prostatic cancer, leukemia

# How to block carcinogen-dependent tumorigenesis

- 1. block **carcinogen uptake** into body/cells
- 2. Inhibition of carcinogen **formation/activation** by blocking Cyp450
- 3. Stimulate **carcinogen deactivation** by conjugation (NAT2, GST, UGT...)
- 4. Inhibition of **DNA adduct formation** (antioxidants)
- 5. Stimulation of **DNA repair**

## 2. **Hormonal** carcinogenesis

- **1. Estrogens**
  - stimulate proliferation of epithelial cells;
  - estrogen metabolites are genotoxic;
- **2. Xeno estrogens**
  - DDE and other insecticides structurally similar to diethylstilbestron;
  - Genistein from Soybean and other phytoestrogens;
  - Digitalis, Sulfonamide antimicrobials,
  - Oral contraception, Hormone Replacement Therapy (estrogen should be counterbalanced by progesteron)

Cancer site	Hormones	Potentially important genes
Breast	Estrogen, progesterone	<i>CYP17, CYP19, HSD17B1, ER, PR</i>
Prostate	Dihydrotestosterone	<i>CYP17, HSD17B3, SRD5A2, AR</i>
Ovary	FSH, progesterone	<i>FSH, FSHR, PR</i>
<b>Endometrium</b>	<b>Estrogen</b>	<i>CYP17, HSD17B1, HSD17B2, ER</i>
Testis	<i>In utero</i> estrogen	<i>CYP17, HSD17B1</i>
Thyroid	TSH, estrogen	<i>TSH, CYP17, HSD17B1</i>

# 3. **Viral** carcinogenesis

- **1. DNA containing oncoviruses**

- Polyomaviridae

- SV40 (monkey, hamster)

- Polyoma (mouse)

- JC and BK viruses (hamster)

- Papillomaviridae

- Human papillomavirus (HPV 16, 18)  
cervical carcinoma

- Adenoviridae

- types 12, 18, 31, 3, 7, 14 (hamster)

- Poxviridae

- myxomavirus (rabbit)

- Jabavirus, tanapoxvirus (benign skin histiocytoma),

- contagiosus mollusc virus (benign pearl-like skin tumors, 5% of Pacific population)

# 3. **Viral** carcinogenesis (cont).

- **1. DNA containing oncoviruses**

- Herpesviridae

- Epstein-Barr virus (EBV)

- Hodgkin disease, nasopharyngeal carcinoma

- Kaposi' sarcoma virus (KHSV)

- Marek disease virus (chicken)

- American rabbit virus

- Hepadnaviridae

- Hepatitis B virus (liver tumors)

- Woodchuck hepatitis virus

- Duck hepatitis virus

# 3. **Viral** carcinogenesis

- **1. RNA containing oncoviruses**

- Alpharetrovirus

- Rous sarcoma virus (RSV),  
Chicken lympholeukosis

- Betaretrovirus

- Mouse mammary tumor virus (MMTV)

- Gammaretrovirus

- Moloney sarcoma virus (mouse)  
Feline sarcoma (FSV)

- Deltaretrovirus

- Bovine leukosis;

- Human adult T-cell leukemia virus (HTLV)**



# Retroviruses

(best understood oncogenic viruses)

## Rous sarcoma virus



1909 Rockefeller Institute

**Chicken sarcoma could be "transferred" into a healthy chicken by grafting tumor cells.**

Cell-free filtrates from the tumor also led to sarcomas in healthy chickens. By 1914, Rous's laboratory had discovered three distinct types of avian sarcomas.

**Virus = "filterable agent"**

**1966 –Nobel Prize  
"for his discovery  
of tumour-inducing viruses"**

## Peyton Rous



Born Baltimore (Maryland)  
**1866-1970**

# Scheme of retrovirus:


"minimal"  
retrovirus

contains

**Env**

**Gag**

**Pol**



Capsid protein  
(gag)

Reverse  
transcriptase  
(pol)

Lipid bilayer

Envelope  
protein  
(env)

RNA

**POL = reverse transcriptase;  
RNA → DNA**

<http://genetherapy.genetics.uiowa.edu/>

**Lipid envelope  
is hijacked from the cell**



**Budding a retrovirus from the cell**

# RETROVIRUS LIFECYCLE

RNA-pol (RT) attached to viral genomic RNA

DNA copies

Random insertions to host genome

Producing of fresh RNAs

Translation → Packaging


Infection

Capsid

Reverse transcriptase

Plasma membrane

Nucleus



Most natural oncogenic viruses are defective:  
not able to propagate without helper virus  
that provides necessary gene products

**Rous sarcoma virus**

(non defective)



**Abelson murine  
Leukemia virus**

(defective, lack Pol and Env genes, added Abl oncogene)



**Harvey sarcoma virus**

(mouse)

(defective, lack Pol and Env genes, added Ras oncogene)



↑                      ↑  
sequences from a  
rat retrovirus, VL30

# Oncogenes (Viral Onc- genes)


- Oncogenes were discovered in “classic” oncogenic viruses (retroviruses)
- (Sarcoma Rous virus) → Src
- (Abelson murine leukemia → Abl

Viral oncogenes have **normal cellular homologues**, that also could be tumorigenic if mutated

v-SRC, v-ABL, v-HA-RAS are derived from host c-ONC sequences (probably picked up as processed transcripts)

# Human Adult T-cell leukemia viruses HTLV-1 and HTLV-2

- **HTLV-1** (human T-cell lymphotropic virus)




- is sexually transmitted;
- endemic to Japan, Caribbean
- causes **Adult T-cell leukemia** (Sezary T-cell leukemia);

## HTLV-2

- T variant of hairy cell leukemia;
- Native Amerindian populations seroprevalence is over

50%.


# Human papillomaviruses HPV6 and HPV18



May integrate into the genome or persist as episomal form

Simplified organisation (linearised) of human papillomavirus type 16 (HPV-16) genome

Expert Reviews in Molecular Medicine



www.tulane.edu

**Causative agents for female cervical carcinomas, as well as for genital and regular warts**



# Human papillomaviruses HPV6 and HPV18

<b>Gene:</b>	<b>Function:</b>
<b>E1</b>	Initiation of DNA replication (helicase)
<b>E2</b>	Transcriptional regulation/DNA replication
<b>E3</b>	???
<b>E4</b>	Late NS protein; Disrupts cytoskeleton?
<b>E5</b>	Transforming protein, interacts with growth factor receptors, e.g. PDGF
<b>E6</b>	Transforming protein, binds to p53 leading to degradation
<b>E7</b>	Transforming protein, binds to pRB
<b>E8</b>	???
<b>L1</b>	Major capsid protein
<b>L2</b>	Minor capsid protein


# Human hepatitis B virus

- **Cause liver cancer (30-50 yrs after infection);**
- **Average life expectancy after diagnosis of liver cancer is 6 months;**
- **DNA virus that encodes 4 genes**
  - Pol – DNA polymerase
  - Env -- envelope
  - pre-core – viral capsid
  - X - activation of host cell genes and the development of cancer.



# Human hepatitis B virus

## Geographic Distribution of Chronic HBV Infection



### HBsAg Prevalence

- >8% - High
- 2-7% - Intermediate
- <2% - Low

# Epstein-Barr virus

Cause infectious mononucleosis;


associated with:

- lymphomas in immunosuppressed persons,
- nasopharyngeal carcinomas
- Burkitt lymphoma (endemic; 8 in every 100,000 children in parts of Africa and Papua New Guinea);
- cofactor for Hodgkin disease (30 yrs after infection);

In Third World nations, most children are infected with EBV;

In most industrialized nations, about 50% of the people are infected.

a EBV genome: latent genes



EBV possess  
a 172 kb genome  
encoding 100 genes.


**EBNAs**  
**1, 2, 3A, 3B and 3C,**  
**and EBNA-LP**  
**= nuclear antigens**

**EBNA-1** is involved in promoting  
viral DNA replication

**EBNA-2** is a transcription factor  
with viral and host cell targets  
**LMP1** expression in rodent cell  
lines

results in transformation  
**LMP2** associates with src  
and several other tyrosine kinases

b Open reading frames for the EBV latent proteins



The Epstein-Barr virus (EBV) genome

# Kaposi's sarcoma virus

[www.kcom.edu/.../lectures/lecture/aids.htm](http://www.kcom.edu/.../lectures/lecture/aids.htm)



HHV-8 virus,  
common in AIDS patients and in  
transplants recipients

**Agent co-infecting  
homosexual men along with HIV**

**KSHV incidence:**

**HIV+ men 25-30%**

**HIV+ women 3-4%**

**HIV+ haemophiliacs 2-3%**


**Virus contains 81 genes;  
including chemokines vMIP1 and vMIP11,  
as well as a chemokine receptor,  
oncogene GPCR and VEGF**

## 4. Bacterial and parasitic carcinogenesis

- 1. **Helicobacter pylori**  
and stomach lymphomas
- 2. **Schistosomiasis**  
and bladder carcinoma



# Helicobacter pylori is linked to MALT lymphoma and gastric carcinoma



*H. pylori*  
overlying  
the gastric epithelial cells.

*H. pylori* causes  
more than 90% of duodenal ulcers  
and up to 80% of gastric ulcers.

**Both cellular and humoral immune responses are activated but the bacteria still manage to persist lifelong unless eradicated with antibiotics.**



# Treatment of gastric and duodenal ulcers

## 1. Lowering of gastric acidity:

(life-long, relapse after cease of therapy)

- H<sub>2</sub> blockers
- proton pump inhibitors.


## 2. 10 days to 2 weeks :

Amoxicillin or metronidazole, or clarithromycin,  
plus either:

ranitidine bismuth citrate or bismuth subsalicylate

**Eradication rates of the range from 61% to 94% depending on the regimen used.**

# Outcomes of H.pylori infection




# Odds ratios for gastric carcinoma

Table 1. *H. pylori* and gastric cancer risk/odds ratio

Group	Risk of gastric cancer
Patients infected with <i>H. pylori</i>	3- to 6-fold risk increase
Patients infected with <i>H. pylori</i> and randomized for prospective serological case-control studies with a follow-up period of at least 14 years	9-fold risk increase
Only patients below age 40	13.3 odds ratio


# Mechanisms of gastric carcinoma induction by H.pylori



# Schistosomiasis

[ehp.niehs.nih.gov/docs/2004/112-2/](http://ehp.niehs.nih.gov/docs/2004/112-2/)

- *Schistosoma mansoni* (intestinal)
- *S. haematobium* (urinary)
- *S. japonicum* (intestinal)
- *S. mekongi* (intestinal)
- *S. intercalatum* (intestinal)



Fresh water snail is an intermediate host.

On contact with humans, the parasite burrows into the skin, matures into another larval stage (schistosomula), then migrates to the lungs and liver (where it matures into the adult form).

The adult worm then migrates to the intestine, liver or bladder

# It affects 200 million people worldwide, mostly in sub-Saharan Africa

## GLOBAL DISTRIBUTION OF SCHISTOSOMIASIS

**Senegal**  
An epidemic of schistosomiasis along the Senegal river basin caused by water-resource development schemes continues unabated.

**Egypt**  
Praziquantel chemotherapy coupled to a vigorous media campaign has resulted in a significant decrease in the morbidity and prevalence of schistosomiasis infection.

**Iran, Morocco, and Saudi Arabia**  
Schistosomiasis control has been successful in those areas with elimination of the infection contemplated.


**China**  
Schistosoma continues to be a major public health problem in the lake and marshy regions despite successful control in other endemic areas.

Schistosomiasis is not usually found in the United States.

**Lao People's Democratic Republic**  
Schistosoma mekongi control has been successful around Khong Island with prevalence reduced from 47% to < 2%.



■ *S. haematobium*  
■ *S. mansoni*  
■ *S. haematobium* and *S. mansoni*  
■ *S. japonicum*



**Djibouti and Somalia**  
Displacement of people by war and instability has introduced intestinal schistosomiasis to these countries.

**North-east Brazil**  
Urban schistosomiasis now present in and around many major cities


**Ghana**  
Intestinal schistosomiasis has increased due to the construction of the Akosombo Dam and other much smaller dams.

**sub-Saharan Africa**  
More than 85% of the estimated 200 million people globally with schistosomiasis and the majority of patients with severe disease live on this continent.

**Indonesia**  
Schistosomiasis has been controlled in the Lindu region of Sulawesi such that the prevalence of infection is lower than 2%.

In Egypt, **schistosomiasis** linked with **cancer** is the primary cause of death among men aged 20 - 44.

[www.dpd.cdc.gov/](http://www.dpd.cdc.gov/)



**Cross-section of different human tissues showing *Schistosoma* sp. eggs. *Schistosoma* sp. in bladder and liver, respectively**

# 5. Inflammatory carcinogenesis

**ALL Pro-inflammatory agents are tumor promoters**  
**Prostaglandins PGE2 and PGF2alpha**

**Phenobarbital that makes a foci in liver**



**Any type of Chronic tissue wounding – tumor can arise on chronic ulcer, burn, trauma site...**

[www.eatonhand.com/handbase/1497905.jpg](http://www.eatonhand.com/handbase/1497905.jpg)

**Anti-inflammatory agents  
can reverse action of tumor promoters**

**anti-inflammatory steroids (dexamethasone)**

**COX inhibitors such as indomethacin, piroxicam and sulindac**



# How the tumor is initiated ?

- 1. Sporadic tumors

(occasional cancers in pedigree, various types of tumors, late onset)

Grandmother (mother line): breast cancer at 83.

Father: prostatic carcinoma at 78. No other cancers in pedigree.

- 2. Inherited cancer syndromes


(same type of cancer in many relatives, early onset)

Grandmother: renal carcinoma at 37.

Father: renal carcinoma at 29.

Son: angioblastoma at 8.

# GENES INVOLVED IN TUMOR DEVELOPMENT



# Classical point of view

```
graph TD; A[Classical point of view] --> B[Oncogenes]; A --> C[Tumor suppressors];
```

## Oncogenes

- Accelerators of cell division
- STOP for apoptosis
- Dominantly inherited  
(one defective allele can predispose the cell to tumor formation)

## Tumor suppressors

- Inhibitors of cell division
- HELP for apoptosis
- Recessive  
(Mutation in one allele predispose human to cancer, but do not cause it)

# WAYS of STATUS CHANGING

## Oncogenes

- Activating point mutations
- Translocation under strong promoter
- Amplification
- Overexpression

## Tumor suppressors

- Inactivating point mutations
- Promotor methylation
- Gross chromosomal deletions
- Underexpression


# MULTISTEP MODEL of the human cancer development

<b>MALIGNANCY</b>	<b>MOLECULAR EVENTS</b>
<b>LEUKEMIA, chronic</b>	<b>2-3</b>
<b>LEUKEMIA, acute</b>	<b>3-4</b>
<b>CARCINOMA, in situ</b>	<b>3-4</b>
<b>CARCINOMA, metastatic</b>	<b>5-12</b>

One molecular event  
(activation of just one oncogene)  
is never enough

# Experiments on oncogene cooperation

Synergistic effect




*myc* alone  
is a weak oncogene,

*ras* alone is somewhat stronger  
an oncogene but still weak,

*myc* and *ras*  
together  
show dramatic  
synergy.

# IN VITRO WE SEE THE SAME EFFECT

## Classical Ras Myc Co-operation (Land *et al*)



*Ras alone*

*Ras + Myc*

*Myc alone*

Fibroblasts with activated *ras* (top) or activated *myc* (bottom) **alone** do not undergo transformation.

However, **co-expression** of activated *ras* and *myc* (middle) does **lead to foci of transformed cells**


# Ras and Myc cooperate as they belong to different signaling cascades

## Cells are “durable”.

Most systems  
have double and triple controls.

To break control of proliferation,

fatal errors should occur  
in two or more signaling cascades





# Tumor suppressor genes



**Have been  
theoretically predicted  
by Alfred Knudson  
in 1971**


(Two-hit hypothesis)

# Familial retinoblastoma




<http://www.djo.harvard.edu/meei/OA>

**a** TSG mutation in a normal cell, leading to sporadic cancer



**b** TSG mutation in a cell with a germline mutation, leading to familial cancer




**Knudson's two-hit hypothesis for tumourigenesis involving a tumour suppressor gene (TSG)**


Expert Reviews in Molecular Medicine ©2001 Cambridge University Press

# Mutation should be in retinal cell

## Two-hit hypothesis and Rb



If 2<sup>nd</sup> mutation  
arises in  
connective tissue



Osteosarcoma

Retinoblastoma

# Two-hit hypothesis relates to TSGs only

**Oncogenes** – activating mutation – damage of one allele is enough.

Gain-of-activity mutation.

One mutation = disease.

---

**Tumor Suppressor Genes** – inactivating mutation – when one allele is damaged, second allele stays functioning.

Loss-of-activity mutation.

One mutation = predisposition. Two mutations = disease.


Most cancer syndromes result from inherited TSG mutations

# Inherited conditions that increase risk for certain cancers


Name of Condition	Type of Cancer
Hereditary retinoblastoma	Retinoblastoma
Xeroderma pigmentosum	Skin
Wilms' tumor	Kidney
Li-Fraumeni syndrome	Sarcomas, brain, breast, leukemia
Familial adenomatous polyposis	Colon, rectum
Paget's disease of bone	Bone
Fanconi's - aplastic anemia	Leukemia, liver, skin

# Strong or weak predisposition to cancer development

## AGE-SPECIFIC CUMULATIVE RISKS FOR BREAST CANCER



# INSTABILITY OF GENOME as a fundamental feature of a cancer cell





# Natural diversity of tumors

**Tumors developed in the same organ  
and presented with the same histology**

**Have the same name**

(e.g. Infiltrating Moderately Differentiated  
Squamous Cell Carcinoma of Lung)

**But molecular picture of mutations in this tumors  
can be totally different**

# The same effect can be obtained by means of any genomic event.

**Nature of event** (type of change) is random;

**Choice of event** (particular gene) is random;


Oncogenes

- Activating point mutations
- Translocation under strong promoter
- Amplification
- Overexpression

Tumor suppressors

- Inactivating point mutations
- Promotor methylation
- Gross chromosomal deletions
- Underexpression

# RATES of molecular events in cancer cells



**Random gain of mutations**

**(low-level; natural cause)**

Early stages of natural cancer in elderly

**Forced gain of mutations**

**(median level; X-ray, chemical carcinogens)**

Early stages of cancer in exposed people


**Very high rate of mutations**

**(cell lost one or more major mechanisms of DNA repair)**

Early stages of cancer in certain syndromes; late stages of almost any cancer

# Naturally occurring mutations

How we can count mutations?



# Human HPRT gene

-- Located on chromosome X

-- Encodes the enzyme **hypoxanthine-guanine phosphoribosyltransferase**

-- Normal function of HPRT is **metabolic salvage of the purine bases hypoxanthine and guanine into nucleotides, inosinic acid, and guanylic acid**

**IN VIVO** complete deficiency of HPRT activity = **too much purines** is Lesch-Nyhan Syndrome (urate crystals + self-Injuring)


Partial deficiency - nephrolithiasis, gouty arthritis, & some neurological manifestations

**Cells can survive without HPRT.**


**Cells are resistant to 6-thioguanine poison ONLY if HPRT gene is mutated**

# HPRT ASSAY

The Hypoxanthine Phosphoribosyltransferase Assay.



Cell that acquired mutation  
in HPRT  
become resistant  
to 6-thioguanine compound




We can directly count mutant colonies and compare this number with number of cell seeded on plate

# HPRT mutation frequency

In peripheral T cells

In 49 healthy,  
non-smoking adults:  
rates varied  $0.25 \text{ -- } 9.64 \times 10^{-6}$ .



What made mutation frequencies  
so different (>10 times)???

1. Polymorphisms of genes metabolizing carcinogens;
2. Polymorphisms of genes responsible for DNA repair;
3. Alcohol consumption and smoking;
4. Exposure to environmental carcinogens;
5. Exposure to radiation

# Experimental check on hypothesis listed above

- 1) **CYP1A1, GSTM1 and NAT2 polymorphisms** have no influence on HPRT mutation frequencies;
- 2) **Mismatch repair genes** was also not damaged;
- 3) Correlation between **maternal alcohol consumption** during pregnancy and results of HPRT assay on T-lymphocytes from newborns?



Early pregnancy alcohol RR of high mutation status = 1.84

Through pregnancy alcohol RR of high mutation status = 2.99

**Smoking during pregnancy**  
have an influence **on mutational spectrum,**  
but **not on mutation frequency**




# Mutations in HPRT and **smoking**



**Yes, smoking increases mutation frequency**



**No, smoke does not have any influence**



**A comparison of mutation frequencies  
in the **K-ras, p53 and HPRT genes****

**between the normal lung tissue of smokers and non-smokers  
indicates that the rate of mutation in smokers  
is only **~1.6 fold higher than in non-smokers****

## 4) Exposure to environmental carcinogens

ethylene oxide ; 1,3-butadiene ; benzene

JUST **marginal increase** in HPRT mutability  
when measured as **in vivo** exposure  
(on plant workers populations)

**Cell line-based or mice/ rat-based**

**HPRT assays**

after direct addition of carcinogen

show **strong increase** in HPRT mutability



## 4) Exposure to radiation



Among Hiroshima-Nagasaki survivors (43 Rad in average)  
HPRT rates : 1 mut per  $10^{-8}$  per base pair per generation  
**indistinguishable from that of Japanese controls**

Chernobyl clean-up workers:

**40% increase in mutation rate**

**in the first year after accident, ....then it declined....**

**Conclusion:** classical HPRT assay in lymphocytes  
do not support any hypothesis explaining population  
variances in mutational load

# Epithelial tissues (carcinoma progenitors)


## In kidney epithelium

- Mut load is  $0.5 - 4.2 \times 10^{-4}$   
– much higher than in lymphocytes  
(10- 100 times higher!)

Such rate is sufficient to account  
for a large proportion of human cancers  
without the need of mutator phenotype


So, at least in kidney carcinogenesis can happens  
without any additional environmental/genetic causes

# COMMON TYPES OF MUTATIONS in human cells



1. Point mutations
2. Microdeletions/microinsertions (1-3 bp)


2 breaks in same arm



3. Large chromosomal deletions
4. Chromosomal insertions and inversions

Paracentric inversion  
Interstitial deletion

5. Translocations
6. Aneuploidy (extra chromosome or chromosomal loss)



# Point mutations (single nucleotide changes)

A → G

G → A

C → T

T → C

} **TRANSITIONS**

**MOST  
COMMON**

PURINE → PURINE or  
PYRIMIDINE → PYRIMIDINE

Pairing is possible  
due to tautomeric shifts or  
ionizing that allows mispairing

A → T

T → G

T → A

G → T

A → C

C → G

C → A

G → C

} **TRANSVERSIONS**

purine → pyrimidine or  
pyrimidine → purine

Pairing is energetically unfavourable,  
but Pur-Pur pairs are possible (G-A)


**When people talk about carcinogenic mutations,  
most often they talk about point mutations.**

**Point mutations much more tolerable  
for cell reparation system,  
As they unlikely to awake apoptosis pathway.**

**On the other hand,  
central pathogenetic event  
in human leukemias and lymphomas  
often is a specific translocation**

**Carcinoma – search for point mutation;  
Lymphoma – search for translocation**

# RATES of molecular events in cancer cells



**Random gain of mutations  
(low-level; natural cause)**

Early stages  
of natural cancer  
in elderly

**Forced gain of mutations**  
(median level; X-ray,  
chemical carcinogens)

Early stages of cancer  
in exposed people


**Very high rate of mutations**  
(cell lost one or more major mechanisms of DNA repair)

Early stages of cancer in certain syndromes;  
late stages of almost any cancer



# INTRACELLULAR SYSTEMS ERRORS

producing high-rate mutations





**Can be classified in three major subtypes**

# TYPES OF INSTABILITY


**MIN**

**(Microsatellite instability)**



**CIN**

**(chromosomal instability)**



**SIN**

**(single nucleotide instability)**

# MIN phenotype (Microsatellite INstability)

progressive accumulation of frameshifts  
in microsatellite repeats

Poly-A and Poly-CA is especially prone; e.g. (A)<sub>6</sub>→(A)<sub>7</sub> or (CA)<sub>5</sub>→(CA)<sub>4</sub>




**Microsatellites as witnesses**  
(innocent bystanders)

Screening for MIN  
can be performed with a panel  
of 5 or more loci  
(D2S123, D5S346, D17S250,  
BAT25, BAT 26)

**Microsatellites in coding  
regions of cancer-involved  
genes**

TGFbetaRII, IGFIIR,  
TCF-4, BAX,  
**hMSH3, hMSH6,**  
CHK1, and BRCA2

# MIN detection on BAT-panel



**three (CA)<sub>n</sub> dinucleotide repeats (D2S123, D5S346, D17S250) and two mononucleotide tracts (BAT 25 and BAT 26).**

# MIN as a DIAGNOSTIC TOOL

**Shorthening of repeats** in subset of cells could be diagnosed


1) both in somatic cells (lymphocytes) and tumor cells of HNPCC patients (colon cancer syndrome);

2) in tumor cell of sporadic cancer patients with MIN + phenotype

**MIN+ → better prognosis for pancreatic and colon carcinomas (better immunoreactivity of the tumor)**

**MIN+ → Worse prognosis for germ cell tumors (testis is immunoprivileged organ)**

**BAT 26**  
1 2



# MIN (Microsatellite INstability)

Family cancer syndromes

Sporadic cancer cases

HNPCC colon cancer

**mutations**

**MSH2**, MSH3, MSH6,

**MLH1**, MLH3,  
PMS1, PMS2 genes

**DNA mismatch repair proteins**

Recognize and bind mismatches,  
especially in microsatellite repeats

**Methylation**

MLH1 or MSH2 promoter

10-15% of gastric carcinomas

30% of sporadic endometrial tumors


30-40% of sporadic breast carcinomas

20% of sporadic colon cancers

Loss-of MSH/MLH gene function – Primary cause of HNPCC colon tumors;  
-- Secondary event in sporadic colon tumors

# SIN - instability

## Recent findings in NCC (Japan)



Single nucleotide instability

Spontaneous Point Mut Rates measured by HPRT system are higher in cancer cell than in normal counterpart

six human breast cancer cell lines (MCF-7, ZR-75-1, T-47D, MDA-MB-231, MDA-MB-468, BT-474), normal human mammary epithelium (HMEC) and a colon cancer cell line (SW480) without microsatellite instability.

# CIN (Chromosomal INstability)

Looks like

LOH  
(loss of  
heterozygosity)

or

Aneuploidy

**LOH Detected as :**

Loss of one allele of  
polymorphic markers  
arranged on the same  
chromosome

(usually by PCR).

**ANEUPLOIDY Detected as:**

Loss or addition of extra copy of  
chromosome


(usually by FISH or  
fluocytometry)



# DETECTION of LOH


Informative microsatellite  
(polymorphic in this particular normal sample)

**TWO alleles in normal tissue**  
versus **ONE allele in tumor tissue**




Pattern of LOH can be different in clinically similar tumors from different patients

(but some loci have LOH more often than others)



Black – homozygous losses;  
white – hemizygous....


# Overlaps of deletions in breast carcinomas



**Two different regions of LOH on the same chromosome are**


**indicative of two different frequently deleted areas**

# LOH appears on a certain stage of tumor development



# Natural difficulties with LOH technics

**1. Every tumor contains normal cells (stromal cells, vasculature, lymphocytes etc...)**



**Normal cell have normal DNA without LOH.**


They contaminate population of tumor cell, and make results unclear.

**2. Homozygous deletions produce no PCR product, that is a situation indistinguishable from failure of PCR reaction**


Deletions can be

**homozygous or hemizygous.**

Hemizygous deletions produce LOH.



# ANEUPLOIDY



Loss or addition  
of **extra copy**  
of **chromosome.**

**Aneuploidy alters the dosages and expression  
of thousands of normal genes  
(most of them are bystanders,  
not a cause of cancer)**

# Cancer-Aneuploidy hypothesis


## Mechanism of Carcinogenesis According to the Aneuploidy-Cancer Hypothesis

Chromosomes and cellular phenotypes

normal

abnormal

cancer



P. Duesberg

Carcinogen  
produce  
aneuploidy



Aneuploidy  
produce  
cancer cell

# Details of Duesberg theory

carcinogens initiate carcinogenesis  
with **a random aneuploidy**

**Aneuploid cells are error prone**

as chromosome segregation  
and maintenance systems

are disbalanced as a result of  
**unbalancing of spindle proteins,  
repair enzymes,  
and centrosome numbers.**

P.Duesberg,  
Nobel prize winner,  
Does not believe in HIV virus



did, after all,  
isolate the first oncogene  
by age 33



# How to measure aneuploidy


## Flow Cytometry

### DNA content flow cytometry

frozen biopsy is thawed and placed in a solution that ruptures the cells leaving only the nuclei

The nuclei are stained with a fluorescent dye that binds to the DNA

The fluorescent dye bound to the nuclear DNA is excited by the light and fluoresces.




intensity or brightness of the cell's fluorescence is proportional to the amount of DNA in the cell

# Telomeres and telomerase: story of extra stability

Reminder: Chromosomes are comprised of a single, uninterrupted DNA molecule complexed with proteins (histones and others).

Telomeres and centromere are demarcating the two “arms” (p and q).

Kinetochores  
microtubules



# Telomeres – Ends of linear chromosomes

**Repetitive** DNA sequence: **TTAGGG** in vertebrates


Associated with specialized proteins.

**Telomeres are necessary because:**

- they allow cells to **distinguish chromosome ends from broken DNA** and prevents chromosomal fusions by non-homologous end-joining (NHEJ) machinery;
- they provide a **mechanism for "counting" cell divisions** as they shorten with each cell division (to be discussed in cancer section)
- they help to **establish 3D structure** of the nucleus

# TELOMERE – story of extra stability


During the replication the lagging strand requires new priming for every piece



As a consequence, every telomere shorten by an amount equal to primer length

It's OK for measuring of the cell life span, it's not OK for maintenance of germ line cells

How to solve telomere maintenance problem?



**Telomerase enzyme is related to reverse transcriptase, as it has a small RNA template as a part of the enzyme structure.**

**Telomerase is highly expressed in germ cells and stem cells**

**Somatic mouse cells express telomerase, that is why they are easier to immortalize; human cell - do not express telomerase.**


**Cancer cells express telomerase !!!**

## Telomerase structure:

Accessory proteins TEP1, p23 and hsp90 also contribute to activity of the complex

P23 and HSP90  
are involved in assembly

TEP1 may facilitate  
DNA binding




# Telomerase and senescence

Germ cells maintain their telomere length.

Telomeres shorten with successive divisions in somatic cells.

At the Hayflick limit (~60 divisions) cells senesce.

Following crisis, a minor population of cells become immortalised and are able to increase their telomere lengths.



Awakening of telomerase

# Different cell types have different requirements for immortalisation

Transfection of hTERT (telomerase) gene to normal human cells gave them an **extra capacity to be passaged appr. 200 times without transforming them to tumor cells**

**TRUE for human fibroblasts  
and for human retinal epithelial cells**

**FALSE for epithelial breast cells:**

**They require: both TEL and del of pRB or p16**

**Some cell type will age  
even if telomerase is re-activated  
(such cells are more tumorigenesis-proof)**



**So, tissue-specific differences are strong !!!**

**CROSS-SPECIES differences can be even stronger!!**

**Everyone should remember it when modeling cancer (or other diseases) in animals**



**Especially in mice, as mice are very weird in sense of their biology**

# MOUSE is very different from human

They are smaller

They life is shorter

# BUT!!!!




They telomeres are longer!!!

They have less stringent regulation  
of telomerase!

mice do not have the barrier  
of telomerase shortening for cell proliferation

Human do have this barrier



Mice cells are easier to immortalize  
in culture compared to human counterparts

Mice are not so protected from tumors like  
human beings (they no need it....)

# MOUSE without a telomerase

TERC<sup>-/-</sup> mouse lack the telomerase RNA component



**Mice are viable AND FERTILE ! No telomerase activity!!!!**

Tissues requiring constant renewing develop normally  
(gut, skin, blood cells)

Generation number 5 (inbred)  
have shorter telomeres  
than those of wild-type and first-generation;

**Decreased fertility and wound healing and,  
as well as an increase of death *in utero* and  
increase in failures of neural tube closure**

# CHEMICAL TUMORIGENESIS IN TELOMERASE DEFICIENT MICE



**TERC<sup>-/-</sup> mice develop less papillomas in multi-stage skin tumorigenesis; only 37% of mice ever develop them. Papillomas regress 1 week after stop of TPA treatment**

# TERT-/- mouse lack the catalytic telomerase component

Looks the same.

After some generations offsprings become prone to pre-mature aging and **tumors!!!**

Contradiction!!!

TERC-/- mice were checked in multi-stage skin tumorigenesis experiments (artificial initiation of the tumors);

In this case absence of telomerase prevents immortalization of mutated cells

TERT-/- mice were checked in **spontaneous tumorigenesis** which is very different from forced tumorigenesis

# Why mice without telomerase are PRONE to spontaneous tumors ?

**As telomeres erode,  
genomic instability is increased  
due to chromosome fusion/breakage.**

**In mice, telomeres can be extended  
by alternative ways ("ALT"),  
accounting for immortalization  
of telomerase-null cells.**

# ALT (alternative lengthening of telomeres)

ALT cell lines are characterized by the combination of **no detectable telomerase activity** and the presence of telomeres **of very heterogeneous length**, ranging from very short to much longer than normal

**ALT telomere lengthening can be maintained by:**

- 1. Another (..mutated..) type of telomerase, that can not be recognised biochemically                      OR**
- 2. could also be caused by retrotransposition or recombination**


# What is the minimal tumor cell? (after all)

**Minimal tumor phenotype  
requires 3 genetic events**

**Expression of Large T-antigen  
(that inactivates RB and p53)**

**hTERT expression  
(telomerase re-activation)**

**Activation of RAS oncogene**



Creation of human tumour cells with defined genetic elements.  
Hahn WC, Counter CM, .....Weinberg RA. *Nature* 99